Sequence: RKKRRQRRRGGGKLLKLLLKLLLKLLK-CONH2
shRNA plasmid (DNA vector expressing shRNA)
| Experiment Id | EXP001865 |
|---|---|
| Paper | Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr–abl fusion gene in Chron |
| Peptide | Tat–LK15 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Example prep (1:1 charge ratio): 0.81 µg peptide in 50 µL HEPES-buffered saline mixed with 1 µg oligo in 50 µL; incubate 30 min RT. Higher charge ratios used for functional assays. |
| Rna Concentration | shRNA plasmid 10–30 µg (within total DNA 30 µg); 4 h transfection then culture 96–192 h |
| Mixing Ratio | (+/−) charge ratio 2:1 (Tat–LK15:plasmid DNA) for silencing studies |
| Formulation Format | Noncovalent electrostatic peptide/nucleic acid complexes |
| Formulation Components | Tat–LK15 fusion peptide complexed with BCR–ABL-targeting siRNA or shRNA expression plasmid (pSilencer 2.0 U6 hygro) |
| Size Nm | 850.00 |
| Zeta Mv | 4.09 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | K562 human chronic myelogenous leukemia cells |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing (BCR–ABL protein by Western blot; mRNA by qRT-PCR) over time |
| Output Value | Up to ~90% BCR–ABL protein reduction at 96 h (30 µg shRNA plasmid); ~85% reduction still at 192 h with highest shRNA dose; mRNA reduced ~70–85% at 48 h |
| Output Units | |
| Output Notes | Compared vs Lipofectamine controls; negative control shRNA shows no effect. |
| Toxicity Notes | MTT: shRNA plasmid complexes show no significant cytotoxicity at 24 h; peptide alone becomes toxic >10 µM. |
| Curation Notes |